Stockscreener 앱 받기
3.65
7.59%
-0.30
시간 외 거래:
3.65
전일 마감가:
$3.95
열려 있는:
$3.96
하루 거래량:
219.43K
Relative Volume:
0.68
시가총액:
$100.87M
수익:
-
순이익/손실:
$-49.81M
주가수익비율:
-1.6929
EPS:
-2.156
순현금흐름:
$-42.93M
1주 성능:
-14.92%
1개월 성능:
-19.25%
6개월 성능:
-58.85%
1년 성능:
-80.77%
1일 변동 폭
$3.65
$4.03
1주일 범위
$3.65
$4.30
52주 변동 폭
$3.56
$19.66
Alto Neuroscience Inc Stock (ANRO) Company Profile
명칭
Alto Neuroscience Inc
전화
773-255-5012
주소
650 CASTRO STREET, SUITE 450, MOUNTAIN VIEW
ANRO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ANRO
Alto Neuroscience Inc
|
3.65 | 100.87M | 0 | -49.81M | -42.93M | -2.156 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.32 | 120.86B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
710.00 | 77.62B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
646.64 | 39.62B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
276.19 | 35.50B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.61 | 28.20B | 3.30B | -501.07M | 1.03B | -2.1146 |
Alto Neuroscience Inc Stock (ANRO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-10-23 | 다운그레이드 | Rodman & Renshaw | Buy → Neutral |
| 2024-10-23 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2024-09-03 | 개시 | Wedbush | Outperform |
| 2024-02-27 | 개시 | Jefferies | Buy |
| 2024-02-27 | 개시 | Robert W. Baird | Outperform |
| 2024-02-27 | 개시 | Stifel | Buy |
| 2024-02-27 | 개시 | TD Cowen | Outperform |
| 2024-02-27 | 개시 | William Blair | Outperform |
모두보기
Alto Neuroscience Inc 주식(ANRO)의 최신 뉴스
Schizophrenia Drugs Market reached US$ 10.03 billion in 2024 - openPR
Alto Neuroscience, Inc. (NYSE:ANRO) Receives $20.00 Average Price Target from Analysts - MarketBeat
Alto Neuroscience announces $75 million ATM offering - MSN
Alto Neuroscience Files For Mixed Shelf Of Up To $300 Million -February 03, 2025 at 05:06 pm EST - Marketscreener.com
Alto Neuroscience announces $75 million ATM offering By Investing.com - Investing.com UK
Alto Neuroscience, Inc. (NYSE:ANRO) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
Precision neuropsychiatry spotlight: a BioCentury podcast - BioCentury
JPMorgan Chase & Co. Acquires 20,536 Shares of Alto Neuroscience, Inc. (NYSE:ANRO) - Defense World
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Alto Neuroscience, Inc. (ANRO) And Encourages Stockholders to Reach Out - ACCESS Newswire
Barclays PLC Raises Stock Position in Alto Neuroscience, Inc. (NYSE:ANRO) - Defense World
Jane Street Group LLC Takes $124,000 Position in Alto Neuroscience, Inc. (NYSE:ANRO) - Defense World
All You Need to Know About Alto Neuroscience, Inc. (ANRO) Rating Upgrade to Buy - Yahoo Finance
Alto Neuroscience, Inc. (NYSE:ANRO) Given Average Rating of “Moderate Buy” by Brokerages - Defense World
Alto Neuroscience, Inc. (NYSE:ANRO) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Alto Neuroscience, Inc. (NYSE:ANRO) Stock Holdings Increased by Geode Capital Management LLC - Defense World
Alto Neuroscience, Inc. (NYSE:ANRO) Shares Bought by Geode Capital Management LLC - MarketBeat
Alto Neuroscience, Inc. (NYSE:ANRO) Shares Acquired by Barclays PLC - Defense World
Alto Neuroscience, Inc. (NYSE:ANRO) Stake Raised by Geode Capital Management LLC - ETF Daily News
State Street Corp Grows Position in Alto Neuroscience, Inc. (NYSE:ANRO) - MarketBeat
Alto Neuroscience, Inc. (NYSE:ANRO) Shares Purchased by State Street Corp - Defense World
Alto Neuroscience Presents Key Data, Study Findings on ALTO-300 - Psychiatric Times
For precision psychiatry, 2024 was one step forward, two steps back - BioWorld Online
Franklin Resources Inc. Buys 595,673 Shares of Alto Neuroscience, Inc. (NYSE:ANRO) - MarketBeat
Alto Neuroscience, Inc. (NYSE:ANRO) Position Boosted by BNP Paribas Financial Markets - Defense World
Charles Schwab Investment Management Inc. Acquires 120,779 Shares of Alto Neuroscience, Inc. (NYSE:ANRO) - Defense World
Jones Trading sets Alto Neuroscience shares at Buy on portfolio By Investing.com - Investing.com Canada
This Addus HomeCare Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
Alto Neuroscience, Inc. (NYSE:ANRO) Sees Significant Drop in Short Interest - MarketBeat
Alto Neuroscience, Inc. (NYSE:ANRO) Shares Bought by The Manufacturers Life Insurance Company - Defense World
Alto Neuroscience, Inc. (NYSE:ANRO) Receives $20.00 Average PT from Analysts - MarketBeat
Alto Neuroscience, Inc. (NYSE:ANRO) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
Alto Neuroscience Announces Data Presented at the 63rd Annual Meeting of the American College of Neuropsychopharmacology - BioSpace
Alto Neuroscience Unveils Breakthrough Precision Psychiatry Data at Major Neuroscience Conference - StockTitan
ANRO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Alto Neuroscience, Inc. and Encourages Investors to Contact the Firm - The Eastern Progress Online
ANRO Investors Have Opportunity to Join Alto Neuroscience, Inc. Fraud Investigation with the Schall Law Firm - The Eastern Progress Online
Fmr LLC Boosts Stake in Alto Neuroscience, Inc. (NYSE:ANRO) - Defense World
Jennison Associates LLC Buys 370,612 Shares of Alto Neuroscience, Inc. (NYSE:ANRO) - MarketBeat
Alto Neuroscience (NYSE:ANRO) Has Debt But No Earnings; Should You Worry? - Simply Wall St
Alto Neuroscience, Inc. (NYSE:ANRO) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
What is William Blair's Forecast for ANRO FY2024 Earnings? - MarketBeat
Wedbush Equities Analysts Reduce Earnings Estimates for ANRO - MarketBeat
RA Capital Management Reduces Stake in Alto Neuroscience Inc - GuruFocus.com
Stifel Nicolaus Has Lowered Expectations for Alto Neuroscience (NYSE:ANRO) Stock Price - MarketBeat
FMR LLC Acquires Shares in Alto Neuroscience Inc - GuruFocus.com
Alto Neuroscience Reports $182M Cash Position Despite Widening Losses in Q3 | ANRO Stock News - StockTitan
Alto Neuroscience Reports Third Quarter 2024 Financial Results and Recent Business Highlights - Yahoo Finance
Latest Company News - Investing.com
Largest borrow rate increases among liquid names - TipRanks
ANRO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC - GlobeNewswire
Alto Neuroscience to Participate in Upcoming Investor Conferences - StockTitan
Bronstein, Gewirtz & Grossman, LLC Is Investigating Alto Neuroscience, Inc. (ANRO) And Encourages Stockholders to Connect - AccessWire
Alto Neuroscience Inc (ANRO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Alto Neuroscience Inc 주식 (ANRO) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Savitz Adam | CHIEF MEDICAL OFFICER |
Jul 10 '24 |
Buy |
13.22 |
2,931 |
38,748 |
39,851 |
| Smith Nicholas Conrad | CHIEF FINANCIAL OFFICER |
Mar 28 '24 |
Buy |
16.36 |
6,150 |
100,628 |
26,866 |
1.03%
자본화:
|
볼륨(24시간):